Latest

09:56
[ Guotai CSI BIOMEDICINE ETF(512290) Rises 3.11%, with Latest Net Capital Inflow of RMB 54.0455 Million ] NewTimeSpace (newtimespace.com) News, – As of 09:50 on August 4, 2026, Guotai Biopharmaceutical ETF (512290) rose 3.11%, with its latest price at RMB 1.03.In terms of liquidity, Guotai Biopharmaceutical ETF recorded a turnover rate of 2.97% during the session, with trading volume reaching RMB 110 million. Over a longer period, as of August 3, the ETF’s average daily turnover over the past month was RMB 210 million.In terms of scale, the latest asset size of Guotai Biopharmaceutical ETF stood at RMB 3.578 billion.
Tag： ETF512290.SHGuotai CSI BIOMEDICINE ETF
09:54
[ Premia China STAR50 ETF (03151.HK) Rises 2.00% in Morning Trade, Turnover Reaches HKD 1.3382 Million ] NewTimeSpace News: As of August 4 at 09:50, Premia China STAR50 ETF (03151.HK) rose 2.00%, with a latest price of HKD 11.220.
Tag： Premia China STAR50 ETFETF03151.HK
09:51
[ CSOP HANG SENG CHINA ENTERPRISES INDEX DAILY (-2X) INVERSE PRODUCT (07588.HK) Rises 1.80% Intraday at HK$1.468 ] NewTimeSpace News: As at 09:46 on August 4, 2026, CSOP HANG SENG CHINA ENTERPRISES INDEX DAILY (-2X) INVERSE PRODUCT (07588.HK) climbed 1.80% to HK$1.468.
Tag： CSOP HANG SENG CHINA ENTERPRISES INDEX DAILY (-2X) INVERSE PRODUCT07588.HKETF
09:50
[ Guotai CSI All Share Communication Equipment ETF (515880) Rises 4.64%, with Latest Margin Buying Amount Reaching RMB 112 Million ] NewTimeSpace (newtimespace.com) News,–As of 09:46 on August 4, 2026, Guotai Communications ETF (515880) rose 4.64%, with its latest price at RMB 0.61.In terms of liquidity, Guotai Communications ETF recorded a turnover rate of 2.34% during the session, with trading volume reaching RMB 927 million. Over a longer period, as of August 3, the ETF’s average daily turnover over the past month was RMB 5.236 billion.In terms of scale, the latest asset size of Guotai Communications ETF stood at RMB 38.087 billion.
Tag： ETF515880.SHGuotai CSI All Share Communication Equipment ETF
09:47
[ CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.54% in Early Trading, NAV Per Unit at HK$3.304 ] NewTimeSpace News: As at 09:42 on August 4, 2026, CSOP Hang Seng Biotech ETF (03174.HK) climbed 2.54% to HK$3.394.
Tag： CSOP Hang Seng Biotech ETF03174.HKETF
09:42
[ Csop Samsung Electronics Daily (-2x) Inverse Product (07347.HK) Rises 2.67% in Early Morning Trading at an Average Price of HK$1.013 ] NewTimeSpace News: As at 09:36 on August 4, 2026, Csop Samsung Electronics Daily (-2x) Inverse Product (07347.HK) climbed 2.67% to HK$1.000.
Tag： Csop Samsung Electronics Daily (-2x) Inverse Product07347.HKETF
08:22
[ ALPHAMAB ONCOLOGY (09966.HK): Enters JSKN016 Licence Agreement with Pathos AI ] NewTimeSpace News: ALPHAMAB ONCOLOGY announced on August 4 that its wholly-owned subsidiary Jiangsu Alphamab entered into a licence agreement with Pathos AI for JSKN016. Pathos AI is granted exclusive rights to research, develop, manufacture and commercialise JSKN016 globally excluding mainland China, Hong Kong, Macau and Taiwan. The upfront payment amounts to US$125 million, with total milestone payments reaching up to US$2.093 billion.
Tag： ALPHAMAB ONCOLOGY09966.HK
08:14
[ CARsgen Therapeutics(02171.HK): CT0596 Secures NMPA IND Approval for Treatment of R/R MM ] NewTimeSpace News: CARsgen Therapeutics announced on August 4 that CT0596, the Company’s allogeneic CAR-T cell product targeting BCMA, has obtained IND approval from the NMPA for the treatment of patients with relapsed/refractory multiple myeloma.
Tag： CARsgen Therapeutics02171.HK
07:48
[ Jiangsu Guofu Hydrogen Energy Equipment (02582.HK): Completes H-share Full Circulation ] NewTimeSpace News: Jiangsu Guofu Hydrogen Energy Equipment announced on August 3 that the procedures for converting 18,416,758 domestic shares of the Company into H-shares were completed on the same day. The converted H-shares will be listed on the Hong Kong Stock Exchange starting from August 4, 2026.
Tag： Jiangsu Guofu Hydrogen Energy Equipment02582.HK
07:42
[ Youzan Technology Limited (06051.HK): Expected First-Half Profit of RMB65 Million to RMB72 Million ] NewTimeSpace News: Youzan Technology Limited announced on August 3 that it expects to record a net profit of approximately RMB65 million to RMB72 million for the six months ended June 30, 2026, compared with RMB73 million in the same period last year.
Tag： Youzan Technology Limited06051.HK
07:34
[ Shaanxi Micot Pharmaceutical Technology (02335.HK): Phase II Trial of MT200605 for Acute Ischemic Stroke Meets Primary Endpoint ] NewTimeSpace News: Shaanxi Micot Pharmaceutical Technology announced on August 3 that the Phase II clinical trial of its self-developed candidate drug MT200605 for the treatment of acute ischemic stroke has achieved the primary efficacy endpoint.
Tag： Shaanxi Micot Pharmaceutical Technology02335.HK
22:11
[ ALPHAMAB-B(09966.HK): CDE Grants Approval for Phase III Clinical Trial of JSKN033 in Cervical Cancer ] NewTimeSpace News: Alphamab Oncology (09966.HK) announced that JSKN033, a high-concentration subcutaneous fixed-dose combination consisting of HER2 bispecific ADC and PD-L1 immune checkpoint inhibitor, has obtained approval from CDE of NMPA to initiate a Phase III clinical study (Trial No. JSKN033-301) as monotherapy for recurrent or metastatic cervical cancer refractory to platinum-based chemotherapy and PD-1/PD-L1 inhibitors. JSKN033 is the world’s first such high-concentration subcutaneous injectable combination product.
Tag： ALPHAMAB-B09966.HKClinical Trial
21:52
[ SF Intra-City (09699.HK): Expected Net Profit for First Half No Less Than RMB301 Million, Surge Over 120% YoY ] NewTimeSpace News: Hangzhou SF Intra-city Industrial Co., Limited (09699.HK) released a positive profit alert. It expects profit attributable to owners of the Company for the first half of 2026 to be no less than RMB301 million, representing a year-on-year increase of no less than 120%; adjusted net profit to be no less than RMB240 million, rising by no less than 50% year-on-year; revenue to be no less than RMB11.669 billion, a year-on-year growth of no less than 14%.
Tag： SF INTRA-CITY09699.HKpositive profit alert
21:37
[ Imagi Int'l (00585.HK): Change of Board Lot Size from 8,000 Shares to 500 Shares, Effective 24 August ] NewTimeSpace News: IMAGI INT'L (00585.HK) announced that the board lot size for its shares will be changed from 8,000 shares to 500 shares, effective 9:00 a.m. on 24 August 2026. Based on the closing price of HK$3.68 per share on the announcement date, the market value per board lot will drop from HK$29,440 to HK$1,840. The Board believes the arrangement will enhance share liquidity and broaden the shareholder base.
Tag： IMAGI INT00585.HKboard lot size
21:09
[ Touyun Biotech (01332.HK): Appointment of Zhou Ruijuan as Executive Director and Vice Chairman ] NewTimeSpace News: Touyun Biotech Group Limited (01332.HK) announced that Ms. Zhou Ruijuan has been appointed as Executive Director and Vice Chairman with effect from 3 August 2026, responsible for the development of the Group’s new materials business. Ms. Zhou holds a Bachelor’s Degree in Management from Lanzhou University and possesses over ten years of senior management experience in the technology and data service industries.
Tag： TOUYUN BIOTECH01332.HKexecutive director
19:50
[ Innogen-B (02591.HK): Two Contract Manufacturing Sites for Isupaglutide α Injection Obtain PIC/S GMP Certificates ] NewTimeSpace News: Guangzhou Innogen Pharmaceutical Group Co., Limited (02591.HK) announced that two contract manufacturing sites in China for Isupaglutide α Injection have passed compliance inspection conducted by Brazil’s ANVISA in accordance with PIC/S GMP standards and obtained relevant GMP certificates, confirming that the production and quality management systems comply with PIC/S GMP requirements.
Tag： INNOGEN-B02591.HKGMP
19:45
[ CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China ] NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the Phase Ib/II clinical trial (SYS6090-008) evaluating the combination therapy of SYS6090 Injection for colorectal cancer developed by the Group has officially been initiated at the first study centre in China. The product is a recombinant fully human anti-PD-1 fusion protein fused with IL-15, classified as Class 1 therapeutic biological product.
Tag： CSPC PHARMA01093.HKClinical Trial
19:01
[ Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies ] NewTimeSpace News: Ascletis Pharma Inc. (01672.HK) announced that once-daily oral small-molecule GLP-1 ASC30 has obtained FDA clearance to initiate global Phase III clinical studies. Two pivotal trials will be conducted in the United States, Europe and Canada, enrolling approximately 4,600 obese or overweight subjects. Meanwhile, the Company disclosed first-in-class oral small-molecule GLP-1/GIP/amylin triple-target fixed-dose combination (FDC) achieved up to 15.2% weight loss in non-human primates, representing a relative improvement of 120% compared with the dual-target formulation.
Tag： ASCLETIS-B01672.HKClinical Trial
18:43
[ WUXI APPTEC(02359.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 11.08 billion, YoY increase of 33.7% ] NewTimeSpace News: August 03, 2026, WUXI APPTEC(02359.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 28.9 billion, increased by 38.94% YoY。
Tag： WuXi AppTec02359.HKprofit growth
18:41
[ SH PHARMA(02607.HK): Omeprazole Sodium Bicarbonate for Oral Suspension (I) Approved for Production ] NewTimeSpace News: SH PHARMA (02607.HK) announced that its subsidiary SPH Xinyi has obtained the Drug Registration Certificate for Omeprazole Sodium Bicarbonate for Oral Suspension (I) issued by the National Medical Products Administration, and the drug is approved for production. Each sachet contains 20mg Omeprazole and 1680mg Sodium Bicarbonate. Classified as Class 3 Chemical Drug, it is mainly indicated for short-term treatment of active duodenal ulcer and gastroesophageal reflux disease.
Tag： SH PHARMA02607.HKDrug Registration Certificate
Previous1..216217 218219220..577     577 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments